Notwithstanding positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant resistance from pharmacy benefit managers. The companies are https://theresablar854864.blogrelation.com/48678458/the-vyndamax-faces-is-encountering-pharmacy-benefit-manager-obstacles-a-look-of-reimbursement-battles